Clinical trial
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated…
NCT00324155 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00324155 |
|---|---|
| Title | Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma |
| Official title | A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Medarex Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Ipilimumab, Placebo, Dacarbazine |
| Enrollment | 681 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Oct 1, 2013 |
| First posted | May 10, 2006 |
| Last update posted | Nov 3, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Hungary, Ireland and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: